<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pharmaceutics-12-00171-t002" orientation="portrait" position="float">
 <object-id pub-id-type="pii">pharmaceutics-12-00171-t002_Table 2</object-id>
 <label>Table 2</label>
 <caption>
  <p>Nano-delivery systems developed for antiviral drugs.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nanoplatform 
     <break/>Type
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nanoplatform Characteristics
     <break/>(Size, Morphology, Toxicity etc.)
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus 
     <break/>Type
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">REF</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Liposomes</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Reverse phase evaporation </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>GCV mixed with PC/CH/NaDC dissolved in chloroform/diethyl;</p>
      </list-item>
      <list-item>
       <p>Spherical liposomes;</p>
      </list-item>
      <list-item>
       <p>Liposome sizes of 210 ± 17 nm, ζ-potential—52.4 mV; polydisperse;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B125-pharmaceutics-12-00171" ref-type="bibr">125</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">- rHDL</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>rHDL-nosiheptide complex with a diameter &lt; 30 nm;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nosiheptide</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HBV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B126-pharmaceutics-12-00171" ref-type="bibr">126</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>rDHL-ACV palmitate complex size of 33.5 nm, around 10 times smaller than ACV-lipososmes;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B127-pharmaceutics-12-00171" ref-type="bibr">127</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- cationic</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Viral gene expression reduce by 65–75% in liver after 2 days of administration at mice;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siRNA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B128-pharmaceutics-12-00171" ref-type="bibr">128</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">- immunoliposomes</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Viral secretion reduced by 81% and free viral particles neutralized in vitro;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV gp 120 Folding inhibitor</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[
     <xref rid="B129-pharmaceutics-12-00171" ref-type="bibr">129</xref>,
     <xref rid="B130-pharmaceutics-12-00171" ref-type="bibr">130</xref>,
     <xref rid="B131-pharmaceutics-12-00171" ref-type="bibr">131</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>In vivo resistance to infection has been enhanced;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">anti-CCR5 siRNA</td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Immunoliposomes diameter with average between 100 and 120 nm; really useful to deliver high concentrations of indinavir;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Indinavir</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- pegylated</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>In house synthesized pis; reduced toxicity and increased adherence in vitro;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PIs</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B132-pharmaceutics-12-00171" ref-type="bibr">132</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Nanoparticles</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- HPAC</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>HPAC (different concentrations)—non-cytotoxic for human epithelial cells (corneal, vaginal), HeLa cells, foreskin fibroblasts: cell viability &gt;75%;</p>
      </list-item>
      <list-item>
       <p>99% drug loading efficiency;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B133-pharmaceutics-12-00171" ref-type="bibr">133</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PLGA</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Three GCV pro-drugs have been separately loaded on PLGA NPs;</p>
      </list-item>
      <list-item>
       <p>Uniform, spherical and smooth surface nps;</p>
      </list-item>
      <list-item>
       <p>Particle size between 116 and 143 nm; ζ-potential between −13.8 and −15 mv;</p>
      </list-item>
      <list-item>
       <p>Non-cytotoxic PLGA-nps (24 h and 48 h contact of three different NPs concentrations with HCEC cell);</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV-1</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B134-pharmaceutics-12-00171" ref-type="bibr">134</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">- Se</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Uniformly spherical Se@AM;</p>
      </list-item>
      <list-item>
       <p>Se@AM size of 70 nm, compared with SeNPs size which is 200 nm;</p>
      </list-item>
      <list-item>
       <p>Se@AM—more stable than SeNPs;</p>
      </list-item>
      <list-item>
       <p>Se@AM—superior antivirial effect on kidney cells treated with H1N1 and less citotoxicity (79.26% viability) than SeNPs (58.8%) or free AM (53.23%);</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AM</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">H1N1</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B135-pharmaceutics-12-00171" ref-type="bibr">135</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Uniformly spherical Se@OTV</p>
      </list-item>
      <list-item>
       <p>Se@OTV size of 100 nm;</p>
      </list-item>
      <list-item>
       <p>Se@OTV—superior antivirial effect on kidney cells treated with H1N1 and less citotoxicity (93% viability) than SeNPs (60%) or free OTV (53%);</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OTV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B136-pharmaceutics-12-00171" ref-type="bibr">136</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Ag</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Monodisperse and uniformly spherical particles;</p>
      </list-item>
      <list-item>
       <p>Ag@AM size of 2 nm; highly stable NPs for more than 28 days;</p>
      </list-item>
      <list-item>
       <p>NPs loaded with AM on their surface less cytotoxic (90%) than free AM (56%) or AgNPs (65%);</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AM</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B137-pharmaceutics-12-00171" ref-type="bibr">137</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PEG-PLGA</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Uniformly spherical shape;</p>
      </list-item>
      <list-item>
       <p>Size of NPs loaded with: diphyllin—178 nm and bafilomycin—197 nm;</p>
      </list-item>
      <list-item>
       <p>Superior biocompatibility and antiviral activity for the drugs loded on NPs than the free drugs;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diphyllin and Bafilomycin</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B138-pharmaceutics-12-00171" ref-type="bibr">138</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Human serum albumin +
     <break/>copolymers of maleic anhydride/alkyl vinyl ethers of oligo (ethylene glycol) 
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Mean size of NPs in the range of 100–300 nm;</p>
      </list-item>
      <list-item>
       <p>NPs surface with targeting moieties able to interact with liver cells receptors;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">INFs-α</td>
    <td rowspan="16" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B139-pharmaceutics-12-00171" ref-type="bibr">139</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Tf-Albumin-PEG</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Spherical particles;</p>
      </list-item>
      <list-item>
       <p>NPs size between 114 and 124 nm; NPs surface had a negative charge;</p>
      </list-item>
     </list>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">AZT</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B113-pharmaceutics-12-00171" ref-type="bibr">113</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Lactoferrin</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Spherical AZT-lactoferrin particles with the diameter in the range of 50–60 nm;</p>
      </list-item>
      <list-item>
       <p>The drug was intact after the preparation process;</p>
      </list-item>
      <list-item>
       <p>AZT encapsulated in lactorferrin NPs is more efficient and less genotoxic (Wistar rats) compared to free AZT;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B140-pharmaceutics-12-00171" ref-type="bibr">140</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PLGA NPs</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Polydisperse particles loaded with LAM with the size between 221 and 250 nm; ζ-potential between −4.64 and −3.65 mv;</p>
      </list-item>
      <list-item>
       <p>The molecular interaction between LAM and the polymer confirmed by FTIR and DSC;</p>
      </list-item>
      <list-item>
       <p>Slow degradation of NPs in simulated intestinal fluid PBS;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LAM</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B141-pharmaceutics-12-00171" ref-type="bibr">141</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Hybrid NPs (PLGA, MMA-SPM, PLA and PMMA)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>PLGA NPs size between 58–224 nm; MMA-SPM NPs size between 91–823 nm;</p>
      </list-item>
      <list-item>
       <p>Almost spherical NPs;</p>
      </list-item>
      <list-item>
       <p>Non-toxic NPs (male mice);</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LAM+AZT</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B142-pharmaceutics-12-00171" ref-type="bibr">142</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PEO-PCL</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Spherical PEO-PCL NPs with smooth surface;</p>
      </list-item>
      <list-item>
       <p>PEO-PCL size around 200 nm, PEO-PCL size around 270 nm; SQV was encapsulated into NPs;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SQV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B143-pharmaceutics-12-00171" ref-type="bibr">143</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PLGA-PEG</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Spherical shape;</p>
      </list-item>
      <list-item>
       <p>Size of the NPs: 125 nm for those loaded with SAHA and NFV; 118 nm for those loaded with NFV; 119 nm for those loaded with SAHA;</p>
      </list-item>
      <list-item>
       <p>Low cytotoxicity effects of NPs loaded with the drugs (tested on ACH-
        <italic>2</italic> cells);
       </p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SAHA
     <break/>NFV
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B144-pharmaceutics-12-00171" ref-type="bibr">144</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PLGA</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Spherical and smooth surface NFV NPs with mean size of 185 nm; an almost narrow distribution; ζ-potential of 28 mV;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NFV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B145-pharmaceutics-12-00171" ref-type="bibr">145</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Lactoferrin</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>NPs mean size of 45–60 nm, hydrodynamic radius of 103 nm, ζ-potential around −23 mV; polydisperse NPs;</p>
      </list-item>
      <list-item>
       <p>Chemically stable NPs proved by FTIR and DSC;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EFV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B146-pharmaceutics-12-00171" ref-type="bibr">146</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Folic acid-conjugated-P407 </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>NPs based on folic acid conjugated with P407 with inclusion of ATV and RTV significantly decreased the amount of HIV produced by cells in mice;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATV+RTV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B147-pharmaceutics-12-00171" ref-type="bibr">147</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PMA coated MNP</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Uniformly spherical NPs conjugated with ENF with size of 35.2 nm and ζ-potential around −29 mV;</p>
      </list-item>
      <list-item>
       <p>Non-toxic in vitro and in vivo NPs conjugated with ENF;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ENF</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B116-pharmaceutics-12-00171" ref-type="bibr">116</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PVA-AOT</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Particles with diameters between 658 and 823 nm; ζ-potential between −12.8 and −25.3 mV;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B148-pharmaceutics-12-00171" ref-type="bibr">148</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- pMBA-Au NPs</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>NPs with diameter of 1.8 nm;</p>
      </list-item>
      <list-item>
       <p>Non-toxic in vitro NPs;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAL</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B130-pharmaceutics-12-00171" ref-type="bibr">130</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PLGA</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>NPs average size of 138.3 nm and ζ-potential around −13.7 mV;</p>
      </list-item>
      <list-item>
       <p>Non-cytotoxic NPs loaded with drugs compared to free NPs;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EFV+Lopinavir+RTV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B149-pharmaceutics-12-00171" ref-type="bibr">149</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PLGA+Pluronic F127</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Well-defined polydisperse NPs with average size of 220 nm and −19.2 mV ζ-potential;</p>
      </list-item>
      <list-item>
       <p>No adverse events and toxicity in a 14 days pharmacokinetic study on mice;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TAF+EVG</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B150-pharmaceutics-12-00171" ref-type="bibr">150</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Lactoferrin</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Average drug loaded particles size of 67 nm;</p>
      </list-item>
      <list-item>
       <p>Insignificant in vitro toxicity to red blood cells;</p>
      </list-item>
      <list-item>
       <p>Improved bioaviability of the three drugs;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AZT+EFV+LAM</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B151-pharmaceutics-12-00171" ref-type="bibr">151</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Dendrimers</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PG</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Non-toxic peptide–PG conjugates in vitro;</p>
      </list-item>
      <list-item>
       <p>Antiviral effect in vitro;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptides</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IAV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B152-pharmaceutics-12-00171" ref-type="bibr">152</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Alginate-PEG</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Dendritic structure confirmed by TEM;</p>
      </list-item>
      <list-item>
       <p>Hydrodynamic diameter in the range of 601–782 nm and ζ-potential in the range of −45.8 and −65 mv;</p>
      </list-item>
      <list-item>
       <p>Great biocompatibility proved by the values of cell viability: between 88% and 98% (neuro cells, Hela cells, glioma cells);</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AZT</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B118-pharmaceutics-12-00171" ref-type="bibr">118</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Nanorods</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- PVP-PEG coated with Ag </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The presence of AM on the surface of Ag nanorods confirmed by FTIR;</p>
      </list-item>
      <list-item>
       <p>The nanorods loaded with AM of 540 nm diameter.</p>
      </list-item>
      <list-item>
       <p>Acceptable viability of cells (hela, huvecs, dendritic cells, macrophages) after 72 h contact with three different concentrations of AM nanorods;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AM</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B153-pharmaceutics-12-00171" ref-type="bibr">153</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Tf-conjugated QRs</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>QR-Tf-SQV hydrodynamic diameter is 130–140 nm;</p>
      </list-item>
      <list-item>
       <p>QR-Tf with different SQV concentrations non-cytotoxic after 6–48 h of contact with BMVECs;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SQV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B154-pharmaceutics-12-00171" ref-type="bibr">154</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Nanospheres</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Cs</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Spherical NS with an almost smooth surface; average diameter around 200 nm, polydisperse NS, ζ-potential around 40 mV;</p>
      </list-item>
      <list-item>
       <p>ACV encapsulation efficiency 86%</p>
      </list-item>
      <list-item>
       <p>Satisfactory Vero cell viability after contact with NS;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B155-pharmaceutics-12-00171" ref-type="bibr">155</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Micelles</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Cs-
     <italic>g</italic>-oligo(NiPAam)
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Copolymers self-assembled into multimicellar aggregates with hydrodynamic diameter between 330 and 436 nm and ζ-potential between +7 and +22.8 mV;</p>
      </list-item>
      <list-item>
       <p>good mucoadhesion and cytocompatibility properties;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EFV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B95-pharmaceutics-12-00171" ref-type="bibr">95</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Nanosuspensions</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- zirconium oxide beads 
     <break/>stabilized with PVP, poloxamers and SLS 
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Mean particele size around 320 nm, ζ-potential −32.8 mV;</p>
      </list-item>
      <list-item>
       <p>EFV bioavailability improved after incorporation in nanosuspensions (in vivo, rabits);</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EFV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B156-pharmaceutics-12-00171" ref-type="bibr">156</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Nanoemulsions</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Mucoadhesive NEs</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Based on triacetin-oil, tween 20-surfactant, transcutol P-cosurfactant;</p>
      </list-item>
      <list-item>
       <p>23–200 nm spherical particles;</p>
      </list-item>
      <list-item>
       <p>Nontoxic and noniritant nanoplatforms (New Zealand albino rabbit);</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B157-pharmaceutics-12-00171" ref-type="bibr">157</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>SLNs</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Borneol</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Microemulsion-based method;</p>
      </list-item>
      <list-item>
       <p>Particle size between 113 and 142 nm; ζ-potential between −15.1 and −18.3 mV; polydisperse particles;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CMV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B158-pharmaceutics-12-00171" ref-type="bibr">158</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Stearic acid + Pluronic F68)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Spherical SLNs with a mean diameter of 167 nm and ζ-potential around −18 mV;</p>
      </list-item>
      <list-item>
       <p>SLNs loaded with AZT can successfully deliver the drug in vitro to human brain endothelial cells;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AZT</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B159-pharmaceutics-12-00171" ref-type="bibr">159</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Lipid nanoparticles</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- bryostatin-2</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>The lipid nanoparticles can stimulate latent HIV and can inhibit virus spread in vitro;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NFV</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B160-pharmaceutics-12-00171" ref-type="bibr">160</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">- PEG and phospholipids</td>
    <td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Size of LNPs loaded with drug/drugs between 33 and 68 nm and incorporation efficiency between 88% and 96%;</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATV+RTV</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[
     <xref rid="B161-pharmaceutics-12-00171" ref-type="bibr">161</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATV+RTV+TFV</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- DSPC+MPEG+DSPE</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <list list-type="bullet">
      <list-item>
       <p>Particle diameter between 52 and 68 nm;</p>
      </list-item>
      <list-item>
       <p>In vivo anti-HIV LNPS do not exhibit local reactions and animal platelet counts are within normal limits.</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liponavir+RTV+TFV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B162-pharmaceutics-12-00171" ref-type="bibr">162</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
